{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:32:21Z","timestamp":1790721141131,"version":"4.1.0"},"reference-count":68,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/03007995.2026.2686032","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:01:26Z","timestamp":1782385286000},"page":"971-985","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed\/refractory multiple myeloma"],"prefix":"10.1080","volume":"42","author":[{"given":"Naresh","family":"Bumma","sequence":"first","affiliation":[{"name":"Hematology, The Ohio State University Comprehensive Cancer Center","place":["Columbus, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research, Sarah Cannon Research Institute","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami Health System","place":["Miami, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[{"name":"Hematology Oncology, Multiple Myeloma and Amyloidosis Program, Karmanos Cancer Institute","place":["Detroit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research (HEOR), Epidemiology & Market Access, Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Garcia-Horton","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research (HEOR), Epidemiology & Market Access, Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research (HEOR), Epidemiology & Market Access, Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Burnett","sequence":"additional","affiliation":[{"name":"Health Economics & Outcomes Research, HB HEOR","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harnett","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Little","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Hematology & Oncology, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Knorr","sequence":"additional","affiliation":[{"name":"Clinical Development, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[{"name":"Translational and Clinical Sciences, Hematology, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanning","family":"Xu","sequence":"additional","affiliation":[{"name":"Hematology Oncology Development, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Regeneron Pharmaceuticals Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.122"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716667275"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205517"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970684.64255.5a"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23261"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_4_10_1","unstructured":"European Medicines Agency. EPAR - Tecvayli [Internet]; 2022; [cited 2023 Dec 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tecvayli-epar-public-assessment-report_en.pdf."},{"key":"e_1_3_4_11_1","unstructured":"US Food and Drug Administration. Drug Approval Package: TECVAYLI [Internet]; 2022 [cited 2026 Jun 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761291Orig1s000TOC.html"},{"key":"e_1_3_4_12_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma [Internet]; 2023 [cited 2023 Sep 29]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma."},{"key":"e_1_3_4_13_1","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Elrexfio [Internet]; 2026 Jan 16 [cited 2026 Mar 11]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elrexfio."},{"key":"e_1_3_4_14_1","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Lynozyfic [Internet]; 2025 Apr 23 [cited 2025 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynozyfic."},{"key":"e_1_3_4_15_1","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma [Internet]. 2025 [cited 2025 Jul 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-linvoseltamab-gcpt-relapsed-or-refractory-multiple-myeloma."},{"key":"e_1_3_4_16_1","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Abecma [Internet]. 2021 [cited 2025 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-abecma_en.pdf."},{"key":"e_1_3_4_17_1","unstructured":"US Food and Drug Administration. BLA Clinical Review and Evaluation BLA 125736 idecabtagene vicleucel [Internet]; 2021 [cited 2025 Sep 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"e_1_3_4_18_1","unstructured":"European Medicines Agency. CHMP summary of positive opinion for Carvykti [Internet]; 2022 [cited 2025 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-carvykti_en.pdf."},{"key":"e_1_3_4_19_1","unstructured":"US Food and Drug Administration. BLA Clinical Review and Evaluation BLA 125746.0 ciltacabtagene autoleucel [Internet]; 2021 [cited 2025 Sep 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti."},{"key":"e_1_3_4_20_1","unstructured":"European Medicines Agency. CHMP change to the terms of the marketing authorisation for Carvykti [Internet]; 2024 [cited 2025 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-carvykti-ii-21_en.pdf."},{"key":"e_1_3_4_21_1","unstructured":"European Medicines Agency. CHMP change to the terms of the marketing authorisation for Abecma [Internet]; 2024 [cited 2025 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-abecma-ii-31_en.pdf."},{"key":"e_1_3_4_22_1","unstructured":"US Food and Drug Administration. Expanded approval ciltacabtagene autoleucel [Internet]; 2024 [cited 2025 Sep 22]. Available from: https:\/\/www.fda.gov\/media\/177564\/download?attachment."},{"key":"e_1_3_4_23_1","unstructured":"US Food and Drug Administration. Expanded approval idecabtagene vicleucel [Internet]; 2024 [cited 2025 Sep 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.03.271"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/11538370-000000000-00000"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocaf030"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2514909"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7531"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7560"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.014"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2139052"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1953456"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/jbm.S507550"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2313628"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02317-6"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03517-7"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03535-9"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01008"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00842"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_4_46_1","unstructured":"ClinicalTrials.gov. A phase 2 multi-cohort open-label multicenter study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma and in subjects with clinical high-risk multiple myeloma (KarMMa-2). [Internet]; 2018 [cited 2018 Dec 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03601078."},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_4_48_1","unstructured":"Phillippo D Ades T Dias S et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE [Internet]; 2016 [cited 2026 Apr 21]. Available from: https:\/\/research-information.bris.ac.uk\/en\/publications\/nice-dsu-technical-support-document-18-methods-for-population-adj\/."},{"key":"e_1_3_4_49_1","unstructured":"Institute for Quality and Efficiency in Health Care. Concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to \u00a735a Social Code Book V (SGB V) [Internet]; 2020 [cited 2025 Sep 22]. Available from: https:\/\/www.iqwig.de\/download\/a19-43_routine-practice-data-for-the-benefit-assessment-of-drugs_extract-of-rapid-report_v1-0.pdf."},{"key":"e_1_3_4_50_1","unstructured":"Wang G. Monthly report: new drug approvals in China [Internet]; 2024 Feb [cited 2026 Apr 21]. https:\/\/baipharm.chemlinked.com\/news\/monthly-report-new-drug-approvals-in-china-february-2024."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.165"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2391553"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913143"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.04.025"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02305-X"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.028"},{"key":"e_1_3_4_57_1","unstructured":"European Medicines Agency. Blenrep [Internet]; 2024 [cited 2025 Sep 22]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blenrep."},{"key":"e_1_3_4_58_1","unstructured":"US Food and Drug Administration. Blenrep (belantamab mafodotin-blmf) [Internet]; 2020 [cited 2025 Sep 22]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0186"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7561"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.312"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235996"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0045"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.013"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021860"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1032775"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2686032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/03007995.2026.2686032","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2026.2686032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:09:56Z","timestamp":1789456196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2026.2686032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/03007995.2026.2686032"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2026.2686032","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}